TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: perceived pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total VTE incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital stay
Endpoint domain: Resource use
Primary endpoint: Shift in auditory thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Allergy Medication Score (AMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum thyroid hormone levels (T3, T4, FT3, FT4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean RT + MT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high-density lipoprotein (HDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin action (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: in-hospital complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Comprehension Index (VCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working Memory Index (WMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptual Reasoning Index (PRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Processing Speed Index (PSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-year secondary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gleason score ≥7 detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biopsy-related complications requiring medical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: change in total symptom score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Locomotor Scores on the GMDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Griffiths Scores on the GMDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Braking response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transient cochlear hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of paresthesic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resistance of the uterine artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Resistance of the palmaris superficial branch of the radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: improvement in functional outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion rate by day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of stroke events
Endpoint domain: Adverse events/effects
Primary endpoint: Primary efficacy endpoint rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SBP control rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: itch/pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: redness (erythema)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A-type Natriuretic Peptide (ANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decompression sickness (DCS) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of venous gas emboli (VGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated dilatation (%FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: reductions in caregiver stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in the percentage of patients with a positive Tinel's sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shortening of sensory and motor latency time in the NCS examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Condom failure rates
Endpoint domain: Adverse events/effects
Primary endpoint: primary end point event rate
Endpoint domain: Mortality/survival
Primary endpoint: major hemorrhage requiring admission
Endpoint domain: Adverse events/effects
Primary endpoint: Mean iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EuroQol 5D Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Kyphotic correction angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative material-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Distress during medical procedures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative complications of VAG
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration below target MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDMT scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation of γδ‐T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proliferation of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in severity of colds and flu symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean percentage decrease in TCM pattern expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: free thyroxine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: thyroid-stimulating hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Digit Span Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post-operative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post-operative sore throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduced neutralising antibody titres to OPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative risk of dying from breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Overall antibiotic prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second-line antibiotic prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QEEG abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PHQ-9 total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental illness symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBF ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery after ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for continuous supply of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of saphenous vein endothelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cervical ectropion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminatory power of models
Endpoint domain: Mortality/survival
Primary endpoint: POD (Patient-Reported Outcome)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tissue density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DVT incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Healthy snack choice
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Proportion of women remaining undelivered at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of women requiring no additional tocolytics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maternal and fetal safety
Endpoint domain: Adverse events/effects
Primary endpoint: Colonization of CVCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of induction-induced hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak FEV1 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of severe asthma exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: ACQ-7 responder rate improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean DAS28 C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: secondary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Development of severe respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in inflammation indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in hepatic steatosis indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of latent TB infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Corneal haze formation
Endpoint domain: Adverse events/effects
Primary endpoint: Repeatability of the VMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: syringol sulfates as biomarkers of smoked meat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscle quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TNFα release from MNCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean number of steps/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intrinsic motivation to be physically active
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum uterine blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5-FU plasma clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thymidylate synthase ternary complex formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: B‐ECOHIS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of postprandial hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative blood levels of WBC, CRP, TNF‐α, and IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incision infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of post-operative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for postnasal packing and blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hamilton and OQ 45.2 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful cecum intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until cecum reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological success at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unpleasant effects (Anxiety, Confusion, decreased Vigor)
Endpoint domain: Adverse events/effects
Primary endpoint: Abuse liability of sibutramine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SMHR (Surface Microhardness Recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAR (Net Antimicrobial Recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete microcirculatory reperfusion (TIMI myocardial perfusion grade = 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete pathologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colon cleansing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerance to sennoside calcium and PEG lavage
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental glycemia at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental glycemia at 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain measured by McGill Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured by McGill Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission rate of patients with AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bFGF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erectile function improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dizziness Handicap Inventory (DHI) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Inventory (DHI) functional subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Inventory (DHI) emotional subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine mean consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants rating themselves as much or very much better
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fulfilling the criteria for fibromyalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tender point counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved <50 HIV‐1 RNA copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in first aid actions taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total seminal leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seminal neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seminal macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Real-time detection rate of EGC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinfection rates of STH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Events of SIRS
Endpoint domain: Adverse events/effects
Primary endpoint: Mean IL-6 level after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strip meniscometry scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RA synovial cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of proinflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total collagenase activity in the joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of control of nausea grade as none or mild
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ≥142 PACs per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiovascular safety of liraglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Saturated fat intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marked improvement in actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: average investigator assessment scale score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change difference from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal incontinence risk
Endpoint domain: Adverse events/effects
Primary endpoint: Proprioception impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol abstinence at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heavy drinking days between 6 and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of implants with bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical bone loss pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal bone loss pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of remaining root filling material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of neuromuscular blockade recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: duration of complete graft healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: complete clinical success after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost and convenience of hypofractionated radiation therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: xerosis score (XS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Ratio (RR) for risperidone versus lithium and divalproex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formula intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained antimicrobial effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative mortality rate
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal pain or discomfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defecation frequency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes